Jefferies analyst Biren Amin noted that Kite Pharma (KITE) reported that all 3 complete responses from the ZUMA-1 study are still ongoing at 9 months follow up and said the company continues to remain confident on its dosing regimen, which is in contrast to some others that reported at ASCO. Amin also noted that Novartis (NVS) presented data in patients with refractory ALL/lymphoma who received prior CAR-T therapy, stating that "while it's early days," there appears to be a path forward for fully human CD19 CAR-T therapy. The firm has Buy ratings on Kite and Novartis shares.